Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(8 sites)

United States

Dana Farber Cancer Institute, Boston, Massachusetts

Albany Medical Center, Albany, New York

Dent Neurologic Institute, Buffalo, New York

Northwell Health, Long Island City, New York

New York Langone, New York, New York

Columbia University, New York, New York

University of North Carolina, Chapel Hill, North Carolina

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania